Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue

Boston Scientific Corporation (NYSE: BSX) today announced positive data from the HI-PEITHO global randomized clinical trial evaluating the use of the EKOS™ Endovascular System in patients with intermediate-risk pulmonary embolism (PE). The study met the composite primary endpoint, with data demonstrating that the EKOS system plus anticoagulation was superior to the current standard of care – anticoagulation alone – for the treatment of acute PE. Findings from the trial were

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the completion of an additional $6 million milestone-based convertible loan to Neurolief Ltd. (“Neurolief”). This second tranche investment was triggered by the recent U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for Neurolief's Proliv™Rx system

UK Biotech Day 2026, taking place on 27–28 May 2026, will be held at the Radisson Hotel & Conference Centre London Heathrow. The event is set to spotlight the strength, global relevance, and collaborative spirit of the UK’s biotechnology ecosystem. It will bring together leaders from industry, research, government, and investment to share ideas, explore new opportunities, and shape the future of life sciences. UK Biotech Day is designed to spark meaningful conversati

Managed Outsource Solutions, a nationwide provider of medical record review services, today announced the launch of ReviewGenX™, an AI-powered medical record review platform developed within its AI ecosystem, DeepKnit AI. The platform is designed to help legal, insurance, healthcare and medical record review organizations improve productivity, analyze records efficiently, while maintaining accuracy, compliance, and defensibility. ReviewGenX applies artificial intelligence, inc

Stern Cardiovascular and Atria Health today announced a strategic partnership that will accelerate access to advanced, physician-led cardiovascular care across Tennessee, Mississippi, Arkansas and surrounding regions. The collaboration brings together Stern's clinical leadership and Atria Health's operational expertise to support Stern's expanded services, new locations, and physician recruitment. Stern Cardiovascular is one of the largest cardiovascular practices in the

Telix Pharmaceuticals Limited today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®1, Floretyrosine F 18 or 18F-FET), an investigational PET2 imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients. Telix has resubmitted the NDA with the additional data requested by the FDA. The Co

Pulse Biosciences, Inc. developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first patient enrollments in the multi-center first-in-human feasibility study of the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for treatment of T1N0M0 papillary thyroid microcarcinoma (PTM), a small, slow-growing, and most common form of thyroid cancer. The initial proce

The WHO Foundation today announced an expanded collaboration with Novo Nordisk to support global efforts to strengthen health systems against the rising burden of cardio-renal-metabolic diseases, including obesity and diabetes. Novo Nordisk has committed a total of USD 7.9 million to support this effort, with an initial gift of USD 2.9 million in 2024 followed by an additional USD 5 million in December 2025. The contribution will enable the WHO Foundation to support WHO

Cairn Surgical, Inc., an innovative medical technology firm striving to make breast cancer surgery more precise, announced today that it has submitted a De Novo 510(k) application to the U.S. Food and Drug Administration (FDA) seeking marketing clearance for its Breast Cancer Locator (BCLTM) System. A medical device can be designated for the De Novo pathway when it offers novel technology with a reasonable assurance of safety and effectiveness for the intended use, and there is no legally mar